Barbara Gruner
Expertise in
1
conditions

Dr. Barbara Gruner

Pediatrics
Curators Of The University Of Missouri
1 Hospital Dr, 
Columbia, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Curators Of The University Of Missouri
1 Hospital Dr, 
Columbia, MO 

Overview

Barbara Gruner is a Pediatrics provider practicing medicine in Columbia, Missouri.

Dr. Gruner is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Hemoglobin SC Disease, Anemia, Leukemia, and Hemophilic Arthropathy.

Dr. Gruner is board certified in American Board Of Pediatrics/Hematology-Oncology. She is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 25 clinical trials.

Graduate Institution

University Of Missouri School Of Medicine

Residency

University of Missouri School of Medicine, Pediatrics

Specialties

Pediatrics

Licenses

Pediatrics in MO

Board Certifications

American Board Of Pediatrics/Hematology-Oncology

Fellowships

University of Texas Health Science Center, Pediatric Hematology-Oncology

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
View 3 Less Insurance Carriers -

Locations

Curators of the University of Missouri
1 Hospital Dr, Columbia, MO 65212

Additional Areas of Focus

Dr. Gruner has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Other, Drug
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Dexrazoxane, Etoposide, Gemtuzumab, Gilteritinib, Liposomal Daunorubicin, Liposomal Cytarabine, Methotrexate, Mitoxantrone, Hydrocortisone
Study Phase: Phase 3
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Completed
Publish Date: June 17, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Enrollment Status: Completed
Publish Date: June 02, 2026
Intervention Type: Drug, Other, Radiation
Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
Enrollment Status: Completed
Publish Date: June 02, 2026
Intervention Type: Other, Drug
Study Drugs: Asparaginase, Bortezomib, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Sorafenib
Study Phase: Phase 3
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
View 9 Less Clinical Trials

7 Total Publications

Anemia Management in Pediatric Chronic Kidney Disease: Current Challenges and Treatment Strategies.
Anemia Management in Pediatric Chronic Kidney Disease: Current Challenges and Treatment Strategies.
Journal: Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
Published: October 15, 2024
Similar Doctors
Expertise in
1
conditions
Expertise in
1
conditions
Referral may be required

Mu General Pediatrics Clinic

551 Veterans United Dr, 
Columbia, MO 
 (5.5 miles away)
573-882-4730
Languages Spoken:
English
See accepted insurances

Kristin Thomas is a Pediatrics provider practicing medicine in Columbia, Missouri. Dr. Thomas is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Autism Spectrum Disorder.

Expertise in
8
conditions
Dr. Ayman W. El-Hattab
Medical Genetics | Pediatrics
Expertise in
8
conditions
Dr. Ayman W. El-Hattab
Medical Genetics | Pediatrics
Referral may be required
402 N Keene St, Ste 101, 
Columbia, MO 
 (2.5 miles away)
573-882-6921
Languages Spoken:
English

Ayman El-Hattab is a Medical Genetics specialist and a Pediatrics provider practicing medicine in Columbia, Missouri. Dr. El-Hattab is highly rated in 8 conditions, according to our data. His clinical expertise encompasses MELAS Syndrome, Neu Laxova Syndrome, Primary Carnitine Deficiency, and Microcephaly.

Expertise in
3
conditions
Dr. Timothy Fete
Pediatrics
Expertise in
3
conditions
Dr. Timothy Fete
Pediatrics
Referral may be required

Curators Of The University Of Missouri

404 N Keene St, 
Columbia, MO 
 (2.5 miles away)
573-882-6882
Languages Spoken:
English

Timothy Fete is a Pediatrics provider practicing medicine in Columbia, Missouri. Dr. Fete is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Clouston Syndrome, Aplasia Cutis Congenita, and Ectodermal Dysplasias.

Frequently Asked Questions about Dr. Barbara Gruner

How do I make an appointment with Dr. Barbara Gruner?

You can book an appointment with Dr. Barbara Gruner by calling their office at 573-882-3961. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Barbara Gruner a top-rated expert for Hemoglobin SC Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Barbara Gruner is classified as an Advanced expert for Hemoglobin SC Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Barbara Gruner specialize in?

While Dr. Barbara Gruner is a Pediatrics, they have specific expertise in Hemoglobin SC Disease, Anemia, and Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Barbara Gruner participate in research or clinical trials?

Yes. Dr. Barbara Gruner has published 7 articles and abstracts on conditions like Hemoglobin SC Disease. You can view a list of Dr. Barbara Gruner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Barbara Gruner accept my insurance?

Dr. Barbara Gruner accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 573-882-3961 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gruner's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile